Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers.

Zhou W, Yang Y, Xia J, Wang H, Salama ME, Xiong W, Xu H, Shetty S, Chen T, Zeng Z, Shi L, Zangari M, Miles R, Bearss D, Tricot G, Zhan F.

Cancer Cell. 2013 Jan 14;23(1):48-62. doi: 10.1016/j.ccr.2012.12.001.

2.

NEK2 mediates ALDH1A1-dependent drug resistance in multiple myeloma.

Yang Y, Zhou W, Xia J, Gu Z, Wendlandt E, Zhan X, Janz S, Tricot G, Zhan F.

Oncotarget. 2014 Dec 15;5(23):11986-97.

3.

Nek2 is a novel regulator of B cell development and immunological response.

Gu Z, Zhou W, Huang J, Yang Y, Wendlandt E, Xu H, He X, Tricot G, Zhan F.

Biomed Res Int. 2014;2014:621082. doi: 10.1155/2014/621082. Epub 2014 Nov 17.

4.

Nek2-targeted ASO or siRNA pretreatment enhances anticancer drug sensitivity in triple‑negative breast cancer cells.

Lee J, Gollahon L.

Int J Oncol. 2013 Mar;42(3):839-47. doi: 10.3892/ijo.2013.1788. Epub 2013 Jan 22.

5.

Hepatoma cell functions modulated by NEK2 are associated with liver cancer progression.

Wu SM, Lin SL, Lee KY, Chuang HC, Feng PH, Cheng WL, Liao CJ, Chi HC, Lin YH, Tsai CY, Chen WJ, Yeh CT, Lin KH.

Int J Cancer. 2017 Apr 1;140(7):1581-1596. doi: 10.1002/ijc.30559. Epub 2017 Jan 19.

PMID:
27925179
6.

Upregulation of NEK2 is associated with drug resistance in ovarian cancer.

Liu X, Gao Y, Lu Y, Zhang J, Li L, Yin F.

Oncol Rep. 2014 Feb;31(2):745-54. doi: 10.3892/or.2013.2910. Epub 2013 Dec 9.

PMID:
24337664
7.

Inhibition of Nek2 by small molecules affects proteasome activity.

Meng L, Carpenter K, Mollard A, Vankayalapati H, Warner SL, Sharma S, Tricot G, Zhan F, Bearss DJ.

Biomed Res Int. 2014;2014:273180. doi: 10.1155/2014/273180. Epub 2014 Sep 17.

8.

Up-regulation of NEK2 by microRNA-128 methylation is associated with poor prognosis in colorectal cancer.

Takahashi Y, Iwaya T, Sawada G, Kurashige J, Matsumura T, Uchi R, Ueo H, Takano Y, Eguchi H, Sudo T, Sugimachi K, Yamamoto H, Doki Y, Mori M, Mimori K.

Ann Surg Oncol. 2014 Jan;21(1):205-12. doi: 10.1245/s10434-013-3264-3. Epub 2013 Sep 18.

PMID:
24046120
9.

Overexpression of NIMA-related kinase 2 is associated with progression and poor prognosis of prostate cancer.

Zeng YR, Han ZD, Wang C, Cai C, Huang YQ, Luo HW, Liu ZZ, Zhuo YJ, Dai QS, Zhao HB, Liang YX, Zhong WD.

BMC Urol. 2015 Aug 29;15:90. doi: 10.1186/s12894-015-0085-7.

10.

NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma.

Huang J, Zhou Y, Thomas GS, Gu Z, Yang Y, Xu H, Tricot G, Zhan F.

Clin Cancer Res. 2015 Dec 15;21(24):5532-42. doi: 10.1158/1078-0432.CCR-15-0254. Epub 2015 Jul 8.

11.

Expression, adverse prognostic significance and therapeutic small molecule inhibition of Polo-like kinase 1 in multiple myeloma.

Evans RP, Dueck G, Sidhu R, Ghosh S, Toman I, Loree J, Bahlis N, Klimowicz AC, Fung J, Jung M, Lai R, Pilarski LM, Belch AR, Reiman T.

Leuk Res. 2011 Dec;35(12):1637-43. doi: 10.1016/j.leukres.2011.07.016. Epub 2011 Aug 3.

PMID:
21816470
12.

Novel small molecules disrupting Hec1/Nek2 interaction ablate tumor progression by triggering Nek2 degradation through a death-trap mechanism.

Hu CM, Zhu J, Guo XE, Chen W, Qiu XL, Ngo B, Chien R, Wang YV, Tsai CY, Wu G, Kim Y, Lopez R, Chamberlin AR, Lee EY, Lee WH.

Oncogene. 2015 Mar 5;34(10):1220-30. doi: 10.1038/onc.2014.67. Epub 2014 Mar 24.

13.

A screen for selective killing of cells with chromosomal instability induced by a spindle checkpoint defect.

Shaukat Z, Wong HW, Nicolson S, Saint RB, Gregory SL.

PLoS One. 2012;7(10):e47447. doi: 10.1371/journal.pone.0047447. Epub 2012 Oct 15.

14.

Novel combination treatment for colorectal cancer using Nek2 siRNA and cisplatin.

Suzuki K, Kokuryo T, Senga T, Yokoyama Y, Nagino M, Hamaguchi M.

Cancer Sci. 2010 May;101(5):1163-9. doi: 10.1111/j.1349-7006.2010.01504.x. Epub 2010 Jan 20.

15.

Nek2 siRNA therapy using a portal venous port-catheter system for liver metastasis in pancreatic cancer.

Kokuryo T, Hibino S, Suzuki K, Watanabe K, Yokoyama Y, Nagino M, Senga T, Hamaguchi M.

Cancer Sci. 2016 Sep;107(9):1315-20. doi: 10.1111/cas.12993. Epub 2016 Aug 12.

16.

Cell cycle-dependent expression of Nek2, a novel human protein kinase related to the NIMA mitotic regulator of Aspergillus nidulans.

Schultz SJ, Fry AM, Sütterlin C, Ried T, Nigg EA.

Cell Growth Differ. 1994 Jun;5(6):625-35.

17.

Examining Nek2 as a better proliferation marker in non-small cell lung cancer prognosis.

Zhong X, Guan X, Dong Q, Yang S, Liu W, Zhang L.

Tumour Biol. 2014 Jul;35(7):7155-62. doi: 10.1007/s13277-014-1935-8. Epub 2014 Apr 25.

PMID:
24763826
18.

Nek2 and Plk4: prognostic markers, drivers of breast tumorigenesis and drug resistance.

Marina M, Saavedra HI.

Front Biosci (Landmark Ed). 2014 Jan 1;19:352-65. Review.

19.

Targeting aurora kinases as therapy in multiple myeloma.

Shi Y, Reiman T, Li W, Maxwell CA, Sen S, Pilarski L, Daniels TR, Penichet ML, Feldman R, Lichtenstein A.

Blood. 2007 May 1;109(9):3915-21. Epub 2007 Jan 9.

20.

Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma.

Anguiano A, Tuchman SA, Acharya C, Salter K, Gasparetto C, Zhan F, Dhodapkar M, Nevins J, Barlogie B, Shaughnessy JD Jr, Potti A.

J Clin Oncol. 2009 Sep 1;27(25):4197-203. doi: 10.1200/JCO.2008.19.1916. Epub 2009 Jul 27. Erratum in: J Clin Oncol. 2012 Apr 20;30(12):1398.

Supplemental Content

Support Center